このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab (APHARIPE)

2026年11月13日 更新者:University Hospital, Caen

Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.

Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.

The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.

調査の概要

状態

まだ募集していません

条件

詳細な説明

Hemophilia is a rare constitutional bleeding disorder. Severe hemophilia A corresponds to a severe factor VIII (FVIII) deficiency (<1%), and moderate hemophilia A to an FVIII level between 1% and 5%. Both forms manifest as spontaneous or post-traumatic/surgical intra-articular bleeds (hemarthroses) or muscle hematomas, which can jeopardize functional prognosis if recurrent.

Until April 2018, the treatment of severe and moderate hemophilia A was exclusively substitutive, relying on intravenous (IV) injections of clotting factor concentrates (FVIII, or bypassing agents such as rFVIIa or aPCC for patients with anti-FVIII inhibitors). Used both prophylactically (2 to 3 IV infusions per week) and on-demand for acute bleeds, this regimen enabled most patients-or family caregivers for younger children-to acquire and maintain autonomy in performing IV injections through frequent practice.

Since April 2018 for patients with inhibitors, March 2020 for severe hemophilia A without inhibitors, and January 2023 for moderate hemophilia A, subcutaneous prophylaxis with the monoclonal antibody emicizumab (Hemlibra®) has been available. While emicizumab converts the bleeding phenotype to that of mild hemophilia, it is strictly prophylactic; IV clotting factor infusions remain required in the event of breakthrough bleeding. Because bleeding events become very rare under emicizumab, the frequency of IV injections drops sharply.

The investigators hypothesize that patients (or family caregivers) who were previously autonomous in performing IV clotting factor infusions progressively lose technical competence and/or self-efficacy during emicizumab prophylaxis. APHARIPE is a multicenter, exploratory, non-interventional questionnaire-based study designed to evaluate patients' and caregivers' perceived loss of autonomy. Healthcare providers caring for this population will also be surveyed to assess potential perception gaps regarding the impact of this loss of autonomy on overall patient management.

The study aims to include 450 patients (or family caregivers) with severe or moderate hemophilia A treated with emicizumab who were previously autonomous for IV injections, over an 18-month recruitment period. Findings will help identify specific difficulties, question the relevance of ongoing IV injection training, assess the impact on acute bleed management and the need to keep emergency treatments at home, and ultimately optimize patient care pathways and therapeutic education practices

研究の種類

観察的

入学 (推定)

450

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Nicolas GUERIN, Registered Nurse
  • 電話番号:+ 33 2 31 06 52 10
  • メール:guerin-n@chu-caen.fr

研究場所

      • Pointe-à-Pitre、グアドループ、97110
        • Centre Hospitalier Universitaire de Pointe à Pitre - Hôpital Ricou
        • コンタクト:
      • Angers、フランス、49933
        • Centre Hospitalier Universitaire d'Angers
        • コンタクト:
      • Bordeaux、フランス、33076
        • Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin
        • コンタクト:
      • Bron、フランス、69677
        • Hospices Civiles de Lyon - Hôpital Louis Pradel
        • コンタクト:
      • Caen、フランス、14000
        • Centre Hospitalier Universitaire de Caen
        • コンタクト:
          • Nicolas GUERIN, Registered Nurse
          • 電話番号:+ 33 2 31 06 52 10
          • メール:guerin-n@chu-caen.fr
      • Chambéry、フランス、73011
      • Clermont-Ferrand、フランス、63000
        • Centre Hospitalier Universitaire de Clermont Ferrand
        • コンタクト:
      • Dijon、フランス、21079
        • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand
        • コンタクト:
      • Grenoble、フランス
        • Centre Hospitalier Universitaire de Grenoble
        • コンタクト:
      • Le Kremlin-Bicêtre、フランス、94275
        • AP-HP - Hôpital Bicêtre
        • コンタクト:
      • Le Mans、フランス
        • Centre Hospitalier du Mans
        • コンタクト:
          • Johann ROSE, Medical Doctor
          • 電話番号:+33 2 44 71 07 50
          • メール:jrose@ch-lemans.fr
      • Lille、フランス、59037
        • Centre Hospitalier Régional Universitaire principal de la métropole lilloise
        • コンタクト:
      • Marseille、フランス、13385
        • AP-HM - Hôpitaux Universitaires de Marseille Timone
        • コンタクト:
      • Montpellier、フランス、34295
        • Centre Hospitalier Universitaire de Montpellier
        • コンタクト:
      • Nantes、フランス、44093
        • Centre Hospitalier Universitaire Hôtel-Dieu
        • コンタクト:
      • Paris、フランス、75679
        • AP-HP - Hôpital Cochin
        • コンタクト:
      • Poitiers、フランス、86021
        • Centre Hospitalier Universitaire de Poitiers - Hôpital Jean Bernard
        • コンタクト:
      • Pringy、フランス、74374
        • Centre Hospitalier Annecy Gennevois
        • コンタクト:
      • Rennes、フランス
        • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
        • コンタクト:
      • Saint-Denis、フランス、97400
        • Centre Hospitalier Universitaire de la Réunion
        • コンタクト:
      • Saint-Etienne、フランス、45055
        • Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord
        • コンタクト:
      • Strasbourg、フランス、67200
        • Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
        • コンタクト:
      • Toulouse、フランス、31059
        • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
        • コンタクト:
      • Tours、フランス、37044
        • Centre Hospitalier Régional Universitaire de Tours - Hôpital Trousseau
        • コンタクト:
      • Vandœuvre-lès-Nancy、フランス、54500
        • Centre Hospitalier Régional Universitaire de Nancy - Hôpital Brabois
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

The study population consists of adult and minor patients with severe (FVIII <1%) or moderate (FVIII 1%-5%) hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year-or parent caregivers (excluding healthcare professionals) for non-autonomous minor patients-who were previously autonomous in performing intravenous clotting factor injections prior to emicizumab initiation. Healthcare professionals (physicians and nurses) involved in the care of these patients will also be enrolled. Participants will be recruited during routine clinical follow-up visits across participating French hemophilia treatment centers

説明

Inclusion Criteria:

For autonomous adult patients (patient enrolled in the study):

  • Adult patient (>= 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained

For autonomous pediatric/minor patients (patient enrolled in the study):

  • Minor patient (< 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained
  • Non-opposition obtained from parents or legal guardians

For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):

  • Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
  • Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Parent caregiver non-opposition obtained

For healthcare providers:

  • Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
  • Healthcare provider non-opposition obtained

Exclusion Criteria:

For autonomous adult patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For autonomous pediatric/minor patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For non-autonomous pediatric/minor patients:

- Parent caregiver who is a healthcare professional

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:OTHER
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Patients or Family Caregivers

Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy

Healthcare Providers

Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Patients or Family Caregivers Reporting a Perceived Loss of Autonomy for Performing Intravenous Clotting Factor Injections
時間枠:At baseline (single questionnaire completion)

Assessed using Question 9 of the study-specific patient/caregiver questionnaire (4-point Likert scale: "not at all autonomous", "slightly autonomous", "moderately autonomous", "completely autonomous"). Responses of "not at all autonomous", "slightly autonomous", or "moderately autonomous" will be classified as a perceived loss of autonomy. Expressed as absolute frequency and percentage of respondents

At baseline (single questionnaire completion)

二次結果の測定

結果測定
メジャーの説明
時間枠
Frequency of Clotting Factor Concentrate Use Under Emicizumab Prophylaxis
時間枠:At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients requiring intravenous clotting factor concentrates (FVIII or bypassing agents) while receiving emicizumab prophylaxis, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Keeping Clotting Factor Concentrates at Home
時間枠:At baseline (single questionnaire completion)

Percentage of patients who report having clotting factor concentrates (FVIII or bypassing agents) stored at home, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting Anticipated Difficulties With Performing a Future Intravenous Injection
時間枠:At baseline (single questionnaire completion)

Percentage of patients or family caregivers who report experiencing or anticipating difficulties in performing a subsequent intravenous clotting factor injection, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Types of Difficulties Encountered During Intravenous Clotting Factor Injections
時間枠:At baseline (single questionnaire completion)

Categorization and percentage distribution of specific technical or psychological difficulties reported by patients or family caregivers when performing intravenous injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Home Nursing Assistance
時間枠:At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for a community nurse (IDE) to perform repeated intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Expressing a Need for a Therapeutic Patient Education Program
時間枠:At baseline (single questionnaire completion)

Percentage of patients reporting the need for therapeutic education sessions to maintain their autonomy in performing intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Initial Intravenous Injection Training
時間枠:At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for initial training to learn how to perform intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Frequency and Quantity of Unused Expired Clotting Factor Concentrates at Home
時間枠:At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients having unused expired FVIII concentrates or bypassing agents at home, along with the total number of expired doses reported via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting an Impact of Perceived Loss of Autonomy on Bleeding Event Management
時間枠:At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients or family caregivers reporting that their perceived loss of autonomy negatively affected the management of an acute bleeding episode, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Patient or Caregiver Autonomy for Intravenous Injections
時間枠:At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to maintain patients' or family caregivers' autonomy for intravenous administration of clotting factor concentrates, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Clotting Factor Concentrates at Home
時間枠:At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to keep emergency clotting factor concentrates at patients' homes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Perceiving a Delay in Bleeding Management Due to Reduced Patient Autonomy
時間枠:At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider that a decreased sense of autonomy for performing intravenous injections delays the management of acute bleeding episodes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Nicolas GUERIN, Registered Nurse、Centre Hospitalier Universitaire de Caen - Centre de Ressources et de Compétences Maladies Hémorragiques Rares

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月15日

一次修了 (推定)

2028年6月30日

研究の完了 (推定)

2028年6月30日

試験登録日

最初に提出

2026年11月13日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する